gdc

Lung Cancer

Molecular Profiling and Immunotherapy Offered Me New Hope After Stage IV Lung Cancer Diagnosis
ImmunotherapyLung CancerPatient StoriesGenomic Testing
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer.
Immunotherapy Brings New Hope for Patients with Non–Small-Cell Lung Cancer and PD-1/PD-L1 Biomarker
BiomarkersImmunotherapyLung Cancer
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial.
Lumakras First FDA-Approved Drug for Advanced Lung Cancer and KRAS G12C Mutation
FDA Approvals, News & UpdatesLung Cancer
In May 2021, the FDA approved Lumakras (sotorasib), an oral KRAS inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer associated with KRAS G12C mutation. Lumakras is the first drug approved for any cancer associated with any KRAS mutation.
Rybrevant First FDA-Approved Therapy for Lung Cancer with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & UpdatesLung Cancer
In May 2021, the FDA approved Rybrevant (amivantamab-vmjw), an intravenous antibody that targets mutations in the EGFR and MET pathways, for the treatment of adults with non–small-cell lung cancer and EGFR exon 20 insertion mutations. This is the first drug approved for lung cancer with EGFR exon 20 insertion mutations.
Lorbrena Approved for First-Line Treatment of Metastatic Lung Cancer with ALK Mutation
FDA Approvals, News & UpdatesLung Cancer
In March 2021, the FDA approved Lorbrena (lorlatinib), a third-generation ALK inhibitor, for first-line treatment of patients with non–small-cell lung cancer and ALK mutation. Lorbrena was previously approved for the second- or third-line treatment for this patient population.
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Myelosuppression in Small-Cell Lung Cancer
FDA Approvals, News & UpdatesLung Cancer
In February 2021, the FDA approved Cosela (trilaciclib) as the first CDK4/6 inhibitor to reduce the risk of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer. Cosela can prevent damage to bone marrow cells by blocking the CDK4/6 enzyme.
Libtayo Approved for First-Line Treatment of Advanced Lung Cancer
FDA Approvals, News & UpdatesLung Cancer
The immunotherapy Libtayo received FDA approval as first-line treatment for patients with advanced or metastatic non–small-cell lung cancer and high PD-L1 expression.
Page 1 of 11
Results 1 - 10 of 104

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest